This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Real Story: Hibernation Time on American Pharma

Shares of American Pharmaceutical Partners (APPX) are down nearly 50% since late November, when the company announced its $4.1 billion takeover of American BioScience. I joined the bear parade in January, with the stock above $37. With American Pharma shares now at $28.29 as of Wednesday's close, after trading at a 52-week low of $27.76 intraday, this grizzly is heading into his cave.

To recap: American Pharmaceutical Partners is tightly controlled by billionaire CEO Dr. Patrick Soon-Shiong. In November, the company said it would spend $4.1 billion to acquire American BioScience, which also happens to be controlled by ( drumroll, please) Dr. Patrick Soon-Shiong.

As reported previously, questions were raised regarding how the company arrived at a $4.1 billion price tag, as no details were released to the public. It turned out that three "independent" board members reviewed and approved the deal. These directors each received a six-figure payment for their efforts. The acquisition is to be completed with stock, diluting current American Pharma investors' holdings by 119%.

As with prior stories, American Pharma did not return calls seeking comment.

The deal actually makes logistical sense. The two companies were splitting the revenue for Abraxane. By combining, the companies can remove some costs and theoretically make the drug more profitable. Abraxane is currently used to treat breast cancer. It is in 74 clinical trials, including some for cancers of the lung, ovaries and prostate. Even if Abraxane turns out to be an effective therapy for these and other cancers, investors have to question whether their best interests will be served by Dr. Soon-Shiong and his board.

My argument against the stock had nothing to do with the company's drugs, sales or pipeline. It centered on the idea that with thousands of public companies to choose from, why would you invest your money with an executive who has proven he will destroy minority shareholders' value in order to enrich himself? On the basis of a flat 80% ownership of American BioScience, Dr. Soon-Shiong's take in the deal is about $2 billion at current market prices.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%
TSLA $226.03 0.00%
YHOO $42.51 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs